Thriving in the field of medical leadership and management, Dr. Prior to her current position, she served as a Physician with the National Health Service (NHS) in the UK, where she made significant contributions to clinical and research initiatives. In this role, she provides strategic direction for the development of new Immuno-Oncology drugs by leading cross-functional teams and conducting medical monitoring of clinical trials. Shreya Badhrinarayanan is the Medical Director for Clinical Development Oncology at Genentech, a subsidiary of Roche. Krankenanstalt Mutterhaus der Borromäerinnen e.V.Dr. Klinikum Region Hannover GmbH, Krankenhaus Siloahīochum, Nordrhein-Westfalen, Germany, 44892Įssen, Nordrhein-Westfalen, Germany, 45122 Rostock, Mecklenburg-Vorpommern, Germany, 18055 Ludwig-Maximilians-Universität München Klinikum Großhadern Mannheim, Baden-Wuerttenberg, Germany, 68167 Hôpital Trousseau - Service de GastroenterologieĬlermont Ferrand, Auvergne, France, 63003 Institut Paoli Calmettes Centre Régional de Lutte Contre le Cancer de Cancerologie Digestive et UrologiqueĬentre Hospitalier Régional Universitaire Hôpital Saint Eloi The Center for Cancer and Blood DisordersĬentre Oscar Lambret, Dept. Joe Arrington Cancer Research and Treatment Center
#Clearview cancer institute santa day Pc#
University of Texas Southwestern Medical Center at DallasĬenter for Cancer and Blood Disorders, PC Kaiser Permanente Northwest Region Oncology Hematology Signal Point Clinical Research Center, LLC New York University Clinical Cancer Center Hematology and Oncology Associates at BridgePoint Suburban Hematology Oncology Associates, PCīoston, Massachusetts, United States, 02111 Peachtree Hematology Oncology Consultants, PC Washington, District of Columbia, United States
New Haven, Connecticut, United States, 06520 TORI Network (Translational Oncology Research Intl) University of California San Diego Medical CenterĬomprehensive Hematology Oncology Centers, Inc. Providence Saint Joseph Medical Center-Disney Family Cancer Center Huntsville, Alabama, United States, 35801Ĭentral Hematology Oncology Medical Group, Inc. Systemic fungal, bacterial, viral, or other infection.Prior irinotecan therapy for metastatic disease is not permitted.Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy) within 21 days prior to randomization.Clinically active liver disease, including active hepatitis (any etiology) or cirrhosis.Uncontrolled hypertension (seated systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) at Screening.Subjects with angina pectoris, poorly controlled ventricular arrhythmias (does not include asymptomatic, occasional premature ventricular contractions), history of clinically significant coronary heart disease or cardiomyopathy, or ECG abnormalities consistent with ischemia.Known dihydropyrimidine dehydrogenase-deficiency (special screening not required).History or presence of any form of cancer, other that colorectal cancer, within the 3 years prior to enrollment.Known or suspected cerebral metastases.Experimental medical treatment within 30 days prior to study entry.More than 1 prior chemotherapy regimen for stage 4 colorectal cancer.No major operations within 4 weeks prior to treatment start.Adequate hepatic and hematologic function.Eastern Cooperative Oncology Group (ECOG) 0-2.Received first line therapy and discontinued part or all of first line therapy.Metastatic Colorectal Carcinoma with KRAS mutation.Recruitment Status, Arms and Interventions, Study Status, Outcome Measures, More Information, Contacts/Locations, Study Design, Study Identification, Adverse Events, Baseline Characteristics, Participant Flow, Eligibility and Study Description Recruitment Status, Contacts/Locations and Study StatusĪrms and Interventions, Study Status, Outcome Measures, Study Design, Study Description and Study Identification Recruitment Status, Study Status and Contacts/LocationsĬontacts/Locations, Study Status and Study IdentificationĬontacts/Locations, Study Status and EligibilityĪrms and Interventions, Study Status, Outcome Measures, Study Description, Contacts/Locations, Eligibility and Study IdentificationĬontacts/Locations, Arms and Interventions and Study Status
0 kommentar(er)
